Literature DB >> 29330698

Circulating Hormones and Mammographic Density in Premenopausal Women.

Kimberly A Bertrand1, A Heather Eliassen2,3, Susan E Hankinson2,3,4, Bernard A Rosner2,5, Rulla M Tamimi2,3.   

Abstract

Prior research suggests that several endogenous hormones in premenopausal women are associated with breast cancer risk; however, few studies have evaluated associations of endogenous hormones with mammographic density (MD) in premenopausal women. We conducted a cross-sectional study of plasma hormone levels in relation to MD among 634 cancer-free premenopausal women in the Nurses' Health Study II. We measured percent MD from screening mammograms using a computer-assisted method. We assayed estradiol, estrone, and estrone sulfate in blood samples timed in early follicular and mid-luteal phases of the menstrual cycle as well as testosterone, androstenedione, progesterone, dehydroepiandrosterone (DHEA), DHEA sulfate, sex hormone-binding globulin (SHBG), and anti-Müllerian hormone in luteal or untimed samples. We used multivariable linear regression to quantify the association of %MD with quartiles of each hormone, adjusting for age, body mass index, and breast cancer risk factors. Women in the highest quartile of follicular estradiol levels had significantly greater %MD compared to those in the lowest quartile [difference, 6.7 percentage points; 95% confidence interval (CI) 2.2, 11.3; p-trend < 0.001]. Similar associations were observed for follicular free estradiol but not luteal-phase estradiol. Also, women in the top (vs. bottom) quartile of free testosterone had significantly lower %MD (difference, - 4.7; 95% CI - 8.7, - 0.8; p-trend = 0.04). Higher SHBG was significantly associated with higher percent MD (difference, 4.8; 95% CI 1.1, 8.6; p-trend = 0.002). Percent MD was not strongly associated with other measured hormones. Results were similar in analyses that excluded women with anovulatory cycles. Our findings suggest that follicular estradiol and SHBG may play an important role in premenopausal percent MD.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29330698      PMCID: PMC5864534          DOI: 10.1007/s12672-017-0321-6

Source DB:  PubMed          Journal:  Horm Cancer        ISSN: 1868-8497            Impact factor:   3.869


  52 in total

1.  Flexible regression models with cubic splines.

Authors:  S Durrleman; R Simon
Journal:  Stat Med       Date:  1989-05       Impact factor: 2.373

2.  Associations among circulating sex hormones, insulin-like growth factor, lipids, and mammographic density in postmenopausal women.

Authors:  Erin J Aiello; Shelley S Tworoger; Yutaka Yasui; Frank Z Stanczyk; John Potter; Cornelia M Ulrich; Melinda Irwin; Anne McTiernan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-06       Impact factor: 4.254

3.  Mammographic densities and circulating hormones: a cross-sectional study in premenopausal women.

Authors:  Jihae J Noh; Gertraud Maskarinec; Ian Pagano; Leo W-K Cheung; Frank Z Stanczyk
Journal:  Breast       Date:  2005-07-05       Impact factor: 4.380

4.  Plasma Anti-Müllerian Hormone Concentrations and Risk of Breast Cancer among Premenopausal Women in the Nurses' Health Studies.

Authors:  A Heather Eliassen; Anne Zeleniuch-Jacquotte; Bernard Rosner; Susan E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-03-09       Impact factor: 4.254

5.  Endogenous sex hormones and breast density in young women.

Authors:  Seungyoun Jung; Frank Z Stanczyk; Brian L Egleston; Linda G Snetselaar; Victor J Stevens; John A Shepherd; Linda Van Horn; Erin S LeBlanc; Kenneth Paris; Catherine Klifa; Joanne F Dorgan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-11-04       Impact factor: 4.254

6.  Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.

Authors:  Stacey A Missmer; A Heather Eliassen; Robert L Barbieri; Susan E Hankinson
Journal:  J Natl Cancer Inst       Date:  2004-12-15       Impact factor: 13.506

7.  Body shape throughout life and correlations with IGFs and GH.

Authors:  Eva S Schernhammer; Shelley S Tworoger; A Heather Eliassen; Stacey A Missmer; Jeff M Holly; Michael N Pollak; Susan E Hankinson
Journal:  Endocr Relat Cancer       Date:  2007-09       Impact factor: 5.678

8.  Urinary estrogens and estrogen metabolites and mammographic density in premenopausal women.

Authors:  Kimberly A Bertrand; A Heather Eliassen; Susan E Hankinson; Gretchen L Gierach; Xia Xu; Bernard Rosner; Regina G Ziegler; Rulla M Tamimi
Journal:  Breast Cancer Res Treat       Date:  2012-09-28       Impact factor: 4.624

9.  The relationship of anthropometric measures to radiological features of the breast in premenopausal women.

Authors:  N F Boyd; G A Lockwood; J W Byng; L E Little; M J Yaffe; D L Tritchler
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640

10.  The association of breast mitogens with mammographic densities.

Authors:  N F Boyd; J Stone; L J Martin; R Jong; E Fishell; M Yaffe; G Hammond; S Minkin
Journal:  Br J Cancer       Date:  2002-10-07       Impact factor: 7.640

View more
  9 in total

1.  Premenopausal Plasma Osteoprotegerin and Breast Cancer Risk: A Case-Control Analysis Nested within the Nurses' Health Study II.

Authors:  Rulla M Tamimi; A Heather Eliassen; Joanne Kotsopoulos; Emma E McGee; Susana Lozano-Esparza; Judy E Garber; Jennifer Ligibel; Laura C Collins; Kornelia Polyak; Myles Brown; Steven Narod
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-04-10       Impact factor: 4.254

2.  Does circulating progesterone mediate the associations of single nucleotide polymorphisms in progesterone receptor (PGR)-related genes with mammographic breast density in premenopausal women?

Authors:  Jingqin Luo; Adetunji T Toriola; Favour A Akinjiyan; Yunan Han
Journal:  Discov Oncol       Date:  2021-11-03

3.  Chemoprevention Agents to Reduce Mammographic Breast Density in Premenopausal Women: A Systematic Review of Clinical Trials.

Authors:  Ana S Salazar; Malika Rakhmankulova; Laura E Simon; Adetunji T Toriola
Journal:  JNCI Cancer Spectr       Date:  2021-01-22

Review 4.  The Other Side of the Coin: May Androgens Have a Role in Breast Cancer Risk?

Authors:  Chiara Chiodo; Catia Morelli; Fabiola Cavaliere; Diego Sisci; Marilena Lanzino
Journal:  Int J Mol Sci       Date:  2021-12-31       Impact factor: 5.923

5.  Does circulating progesterone mediate the associations of single nucleotide polymorphisms in progesterone receptor (PGR)-related genes with mammographic breast density in premenopausal women?

Authors:  Jingqin Luo; Adetunji T Toriola; Favour A Akinjiyan; Yunan Han
Journal:  Discov Oncol       Date:  2021-11-03

6.  Evaluation of the association of endometriosis and mammographic breast density, a cross-sectional study.

Authors:  Ashraf Moini; Elnaz Salari; Hadi Rashidi; Khadije Maajani; Mahboubeh Abedi; Leila Bayani; Sadaf Alipour
Journal:  BMC Womens Health       Date:  2022-03-21       Impact factor: 2.809

7.  Relationship of Serum Progesterone and Progesterone Metabolites with Mammographic Breast Density and Terminal Ductal Lobular Unit Involution among Women Undergoing Diagnostic Breast Biopsy.

Authors:  Manila Hada; Hannah Oh; Shaoqi Fan; Roni T Falk; Berta Geller; Pamela Vacek; Donald Weaver; John Shepherd; Jeff Wang; Bo Fan; Sally Herschorn; Louise A Brinton; Xia Xu; Mark E Sherman; Britton Trabert; Gretchen L Gierach
Journal:  J Clin Med       Date:  2020-01-17       Impact factor: 4.241

8.  Hormonal determinants of mammographic density and density change.

Authors:  Marike Gabrielson; Shadi Azam; Elina Hardell; Madeleine Holm; Kumari A Ubhayasekera; Mikael Eriksson; Magnus Bäcklund; Jonas Bergquist; Kamila Czene; Per Hall
Journal:  Breast Cancer Res       Date:  2020-08-26       Impact factor: 6.466

9.  Biomarkers of mammographic density in premenopausal women.

Authors:  Mathilde His; Martin Lajous; Liliana Gómez-Flores-Ramos; Adriana Monge; Laure Dossus; Vivian Viallon; Audrey Gicquiau; Carine Biessy; Marc J Gunter; Sabina Rinaldi
Journal:  Breast Cancer Res       Date:  2021-07-23       Impact factor: 6.466

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.